Tirzepatide and semaglutide were associated with larger QALY gains (incremental gains of 0.35 and 0.25 over lifestyle ...

SAN DIEGO -- Two retrospective studies hinted at potential negative effects of GLP-1 receptor agonists for patients requiring ...

Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat ...

Both semaglutide and tirzepatide should help people with Type 2 diabetes lower their HbA1c, a measure of blood glucose over ...

Q. I have something like varicose veins in my nose that cause frequent nosebleeds. My nose is often dry regardless of weather conditions.

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Q4 2024 Earnings Call Transcript March 3, 2025 Fractyl Health, Inc. Common Stock misses on earnings expectations. Reported EPS is $-0.52 EPS, expectations were $-0.44. Operator: Good afternoon, and ...

The FDA's updated guidance extends the enforcement discretion for compounding semaglutide, a medication relevant to Hims & Hers offerings, until April 22, 2025, or until a court decision is made ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...